List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act
NonrulemakingNoticeFDA-2018-N-3240-0377
Comments
624
Awaiting comments
Deadline
17 days
Closes Jul 1, 2026
Net support
+32%
Support minus oppose · campaigns included
+32% excluding campaigns
Document
Details
The document's own metadata, straight from regulations.gov.
- Posted
- May 1, 2026
- Comment period
- May 1, 2026 – Jul 1, 2026
- Agency
- Food and Drug Administration (FDA)
- FR Doc
- 2026-08552
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Analyzed 355 of 624 comments
57%· analysis in progress
Stance breakdown
+32%
Net support
Support232Oppose118Other5Not yet analyzed269
Aggregates include form-letter campaigns. Excluding them, net support is +32% across organic comments.
Who commented
Breakdown by commenter type.
Business
1
Individual
353
Advocacy
1
Not yet analyzed
269
Comments over time
Weekly arrivals, stacked by stance.
Posted May 1, 2026Deadline Jul 1, 2026
Support232Oppose118Other5
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to filter the Explorer.
Issues are identified as comment analysis progresses — nothing tagged on this document yet.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
Read all 624 comments
The Explorer — every comment with stance, commenter type, and AI summaries — is part of the paid plan. $180/month per seat, 30-day money-back guarantee.